In a groundbreaking achievement, President Droupadi Murmu recently launched India’s first domestically developed CAR T-cell therapy for cancer treatment. This significant milestone marks a new era in the fight against cancer, offering hope to patients across the nation.
What Is CAR T-Cell Therapy?
CAR T-cell therapy (Chimeric Antigen Receptor T-cell therapy) is an innovative immunotherapy approach that harnesses the power of a patient’s own immune system to combat cancer.
Here’s how it works:
Collection: T-cells (a type of immune cell) are extracted from the patient’s blood.
Modification: These T-cells are genetically modified in the laboratory to express a chimeric antigen receptor (CAR) specific to cancer cells.
Infusion: The modified T-cells are then infused back into the patient’s body.
Targeting Cancer: The CAR T-cells recognize and attack cancer cells, leading to their destruction.
India’s Homegrown CAR T-Cell Therapy
Developed jointly by the Indian Institute of Technology (IIT) Bombay and the Tata Memorial Centre, this gene-based therapy has been prepared within India at approximately one-tenth of the cost compared to its international counterparts. The collaboration between these institutions has resulted in a groundbreaking achievement that showcases India’s scientific prowess.
Key Highlights:
Indigenous Development: The therapy is a shining example of the “Make in India” initiative, emphasizing self-reliance and innovation.
Customized Treatment: Each patient’s CAR T-cells are customized in the laboratory, making it a tailored solution for every individual.
Cost-Effective: The therapy is significantly more affordable than similar treatments available abroad, with a cost of approximately 30 lakhs INR compared to around 4 crores INR internationally12.
President Droupadi Murmu’s Role
During the launch event at IIT Bombay, President Murmu highlighted the unprecedented progress in medical science achieved through this therapy. She stated, “The development of this therapy is a testament to Indian scientists and doctors. It not only represents a scientific breakthrough but also provides renewed hope for humanity in the battle against cancer.”
A New Dawn in Cancer Treatment
NexCar19 CAR T-Cell Therapy is India’s first “Made in India” CAR T-cell therapy. Its affordability and accessibility hold immense promise for cancer patients, positioning India firmly on the global map of cell and gene therapies.
As we celebrate this remarkable achievement, let us recognize the tireless efforts of our scientists, clinicians, and institutions. President Droupadi Murmu’s launch of this indigenous therapy marks a significant step forward in our fight against cancer, offering a beacon of hope for countless lives.
